The European Medicines Agency’s Committee for Medicinal Products for Human Use recommended three medicines for approval and eight extensions at its April 23-26 meeting.

The committee endorsed a marketing authorization for Gilead’s HIV-1 treatment Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide).

The CHMP recommended approval of  Carmustine Obvius (carmustine) a generic drug for treatment  Hodgkin’s disease, non-Hodgkin’s lymphoma and brain tumors.

It also issued a positive opinion for the pain treatment Dzuveo (sufentanil).